Safety and Efficacy of Middle Meningeal Artery Embolization for the Treatment of Migraine.

Prior treatment

• Patients planning to undergo surgery within 90 days;
• Subjects who participated in other clinical trials of drugs or medical devices before enrollment and did not reach the time limit of the primary study endpoint;

Other illness

• Findings on cerebral angiography indicating secondary headache due to intracranial vascular disorders, including dural arteriovenous fistula, arteriovenous malformation, venous malformation, or other relevant cerebrovascular lesions; Moyamoya disease; or high-risk vascular anatomical variants unsuitable for safe vascular access or contraindicating MMA embolization.
• Complicated with cervical spondylosis and secondary headache of otogenic, rhinogenic, odontogenic origin; patients with a history of trigeminal autonomic cephalalgias; headache with other definite etiologies or secondary headache;
• Patients with a definite history of contrast media allergy;
• Patients with a history of opioid addiction;
• Patients with a definite history of allergy to embolization materials such as nitinol alloy and/or cobalt-based alloy, platinum-tungsten alloy, etc.;
• Other conditions in which the investigator considers the patient inappropriate to participate in this study.

Other

• Imaging diagnosis shows acute or chronic subdural hematoma, other acute intracranial lesions and other space-occupying lesions;
• Patients with a life expectancy of less than 12 months;
• Breastfeeding or pregnant women, or patients with fertility plans within half a year;
• Unable to understand headache-related assessment data such as headache diaries and requiring assistance from others to complete them;
• Patients with poor compliance judged by the investigator and unable to complete the study as required;
• Subjects with other comorbidities that restrict their participation in the study, prevent compliance with follow-up, or affect the scientific integrity of the study;

• Age 18\~80 years old (inclusive), regardless of gender.
• Voluntary written informed consent.
• Migraine diagnosed by neurologists/pain specialists according to the current International Classification of Headache Disorders, 3rd Edition (ICHD-3) criteria for migraine with or without aura.
• Migraine attack frequency of no less than 4 days per month within one month prior to enrollment.
• History of pharmacotherapy for migraine prophylaxis or treatment for at least 6 months.